Polycystin-1 transforms the cAMP growth-responsive phenotype of M-1 cells  by Sutters, Michael et al.
Kidney International, Vol. 60 (2001), pp. 484–494
Polycystin-1 transforms the cAMP growth-responsive
phenotype of M-1 cells
MICHAEL SUTTERS,1 TAMIO YAMAGUCHI,1 ROBIN L. MASER,1 BRENDA S. MAGENHEIMER,
PATRICIA L. ST. JOHN, DALE R. ABRAHAMSON, JARED J. GRANTHAM, and JAMES P. CALVET
Departments of Biochemistry and Molecular Biology, Medicine, and Anatomy and Cell Biology, University of Kansas Medical
Center, Kansas City, Kansas, USA
Polycystin-1 transforms the cAMP growth-responsive pheno- [3–5] or an autosomal-recessive trait (ARPKD) [6].
type of M-1 cells. ADPKD is a common disease, with a gene frequency of
Background. Polycystic kidney disease (PKD) is character- 1 in 200 to 1000 individuals, and gives rise to 6 to 9%ized by the abnormal proliferation of tubular epithelial cells.
of all end-stage renal disease [1]. Mutations in the PKD1It was recently shown that the growth of PKD cyst-lining cells
gene [7–9] are responsible for 85 to 90% of ADPKDis stimulated by cyclic adenosine monophosphate (cAMP),
whereas the growth of normal human kidney cortex cells is cases, while mutations in the PKD2 gene [10] account
inhibited. for most, if not all of the remaining ADPKD cases.
Methods. We have examined the effects of overexpressing The PKD1 gene product, polycystin-1, is a 4302-aminothe C-terminal cytosolic tail of mouse polycystin-1, as a mem-
acid, membrane-associated protein with a large N-termi-brane-targeted fusion protein, on cAMP-responsive cell prolif-
nal extracellular domain and a smaller C-terminal cyto-eration in stably transfected M-1 cortical collecting duct cells.
Two cell lines that express high levels of the polycystin-1 fusion solic domain. A number of protein motifs have been
protein and two control cell lines that do not express the fusion identified in polycystin-1 that include two leucine-rich
protein were tested. repeats, a C-type lectin domain, an LDL-A domain, a
Results. Growth of parental M-1 cells and the control cell
set of 16 tandem immunoglobulin (Ig)-like PKD repeats,lines was inhibited by 8-Br-cAMP and by a variety of cAMP
an REJ domain, a PLAT domain, a GPS domain, andagonists. In contrast, growth of the polycystin-1–expressing
clones was stimulated by cAMP. Consistent with this, the pro- 7 to 11 transmembrane domains followed by a C-terminal
tein kinase A (PKA) inhibitor H-89 caused either a positive cytoplasmic tail [8, 11–15]. A number of these domains
or a negative growth effect depending on the primary response are found in proteins that are involved in cell adhesion
to cAMP. PD98059 blocked the cAMP stimulation of cell pro- or that function as plasma membrane receptors [16–20].liferation, indicating that the pathway is MEK1 dependent.
Indeed, the Ig-like repeats have been shown to promoteConclusions. Expression of the polycystin-1 C-terminal tail
strong homophilic cell–cell adhesive interactions [21].disrupts normal cellular signaling and transforms the stably
transfected M-1 cells to an abnormal PKD cell proliferation The PKD2 gene product, polycystin-2, has sequence sim-
phenotype. ilarity to a family of voltage-activated cation channels,
and interacts with the TRPC1 channel [10, 22, 23]. Sev-
eral recent studies have provided evidence that polycys-
Polycystic kidney disease (PKD) is characterized by tin-2 is a nonspecific Ca2-permeable cation channel [22,
the growth of large epithelial-lined cysts from the tubules 24, 25]. Hybridization and immunocytochemical analyses
of affected kidneys [1] and by extrarenal manifestations have shown that the PKD1 and PKD2 genes are widely
that affect a number of organ systems [2]. The disease is expressed in a number of embryonic and adult tissues
inherited as either an autosomal-dominant trait (ADPKD) and organs [26–31].
Most of the mutations in the human PKD1 and PKD2
genes appear to lead to premature termination of transla-
1 All three authors contributed equally to this work. tion and/or protein truncation [32–36]. A loss-of-function
mechanism is supported by Pkd1 and Pkd2 knockoutKey words: polycystic kidney disease, stable transfection, cell prolifera-
tion, signal transduction. mice [37–40], which have late-embryo lethal phenotypes
as homozygotes and slowly progressive PKD as heterozy-Received for publication November 21, 2000
gotes; however, transgenic overexpression of the Pkd1and in revised form February 9, 2001
Accepted for publication March 13, 2001 gene can also give rise to PKD [41], suggesting that either
a dominant negative or a gain-of-function mechanism 2001 by the International Society of Nephrology
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can also lead to a disease phenotype. Several studies have ence of cyclic adenosine monophosphate (cAMP) ago-
nists [68, 69]. It was shown in these studies that in contrastprovided evidence for somatic mutation or loss of hetero-
zygosity of the PKD1 and PKD2 genes in cyst-lining epi- to the normal cells, whose proliferation is either not
affected [69] or inhibited [68] by cAMP, the proliferationthelial cells [42–46]. In such cases, the somatic second-
hit event is thought to provide a growth advantage to a of the cyst-lining cells is stimulated by cAMP. It is possi-
ble that this change in the phenotype of the ADPKDcell, resulting in increased cell proliferation and ulti-
mately giving rise to the clonal expansion of the popula- cells is due to disrupted function of the PKD1 or PKD2
genes. To test this hypothesis, we developed mouse corti-tion of cells comprising a cyst.
Abnormal cell proliferation is recognized as an impor- cal collecting duct (M-1) cell lines stably expressing a
membrane targeted, inducible polycystin-1 C-terminaltant process in cyst growth in PKD [47]. Cystic kidneys
are characterized by hyperplastic epithelium and other construct to determine whether the expression of this
truncated fusion protein would affect the phenotype ofcellular changes, including the appearance of cells with
a transformed phenotype and the outgrowth of papillae these cells. Our results show that overexpression of the
polycystin C-terminal tail in these cells converts the phe-or micropolyps from the cyst wall epithelium [48]. In-
creased cell proliferation is also evident from gross inspec- notype from one in which cell proliferation is inhibited
by cAMP to one in which cell proliferation is stimulatedtion of cystic kidneys, where it can be seen that tubules
that are only a few cells in circumference grow to cysts by cAMP. Thus, it appears that overexpression of this
polycystin-1 fusion construct can transform M-1 cellsthat reach a size of millimeters to centimeters in diameter
and are comprised of large numbers of cells as deter- from a normal collecting duct phenotype to an ADPKD
phenotype, suggesting that the abnormal cAMP-respon-mined microscopically [49]. The aberrant cell growth
in cystic kidneys also is consistent with the abnormal sive cell growth phenotype of ADPKD cells is caused
by disruption of the polycystin-1 signaling pathway.expression of genes associated with the regulation of cell
proliferation (c-myc, c-fos/c-jun, Ha-ras/Ki-ras, PCNA)
[50–56] and by the fact that transgenic overexpression
METHODS
of either c-Myc [57] or SV40 Large T [58, 59] can give
DNA constructsrise to PKD.
A number of studies have provided direct evidence For production of stably transfected cell lines, the por-
tion of a mouse Pkd1 cDNA (from a 2.6 kb, 3 end clone,connecting polycystin-1 function to known signaling path-
ways [60–62]. Constructs containing the C-terminal cyto- provided by P. Seranski and G. Germino) encoding the
C-terminal–most 193 amino acids of polycystin-1 was sub-solic domain of human polycystin-1 are able to stimulate
activator protein-1 (AP-1) promoter activity in transiently cloned together with the membrane targeting cassette sIg.7
(from clone sIg.7-PKD1MN6, provided by G. Walz) intotransfected mammalian cells by protein kinase C (PKC)-
and c-Jun N-terminal kinase (JNK)-dependent mecha- either the dexamethasone-inducible pLK-neo [70] or the
IPTG-inducible pOPRSVI/MCS (LacSwitch II System;nisms [60]. The C-terminal domain has also been demon-
strated to bind and activate heterotrimeric G-proteins Stratagene, La Jolla, CA, USA) eukaryotic expression
vectors to create a construct encoding the sIg-PKD193[63], to be a target for phosphorylation by protein kinase
A (PKA) and a Src-like tyrosine kinase [64, 65], and fusion protein (Fig. 1). A control construct, sIg-0, encod-
ing only sIg.7 and lacking polycystin-1 sequences, wasto bind RGS7, a regulator of heterotrimeric G-protein
signaling [61]. It has also been shown that the C-terminal also produced in pLK-neo and pOPRSVI/MCS (Fig. 1).
For Northern blot hybridizations, portions of the mousetail of polycystin-1 stimulates the Wnt signaling pathway
through the inhibition of glycogen synthase kinase-3 Pkd1 cDNA encoding amino acids 4101 to 4293 (3 probe)
or amino acids 3337 to 3735 (internal probe) were sub-(GSK-3) and the subsequent stabilization of -catenin
[62]. In addition, the C-terminal domains of polycystin-1 cloned into transcription vectors for production of anti-
sense RNA probes.and polycystin-2 are thought to interact directly with
each other, possibly via a coiled-coil interaction [66, 67],
Tissue culturesuggesting that the two proteins function together as
part of a multiprotein membrane signaling complex [24]. M-1 cells, which were derived from microdissected
cortical collecting duct of a mouse transgenic for SV40However, despite this biochemical evidence for polycys-
tin-1 function, it is not clear how mutations in the PKD Large T antigen [71], were used as the parental line to
generate stably transfected cell lines expressing the sIg-genes lead to the increased cell proliferation associated
with the initiation of cyst formation. PKD193 and sIg-0 fusion proteins. Cells were maintained
in Dulbecco’s modified Eagle’s medium (DMEM)/F12Two recent studies have shown that normal human kid-
ney cortical epithelial cells and cyst-lining epithelial cells (50:50) with penicillin, streptomycin, and 5% fetal bovine
serum (FBS). For production of stably transfected cellfrom human ADPKD polycystic kidneys respond quite
differently when grown in primary cultures in the pres- lines, the pLK-neo sIg-constructs were introduced into
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the M-1 cells by lipofectin-mediated transfection, and USA), blocked in TBST (10 mmol/L Tris-HCl, pH 7.4,
0.9% NaCl, 0.1% Tween 20) with 5% powdered milk,the cells were grown in selection medium containing
300 g/mL G418. G418-resistant clonal cell lines were and probed with either a goat anti-human IgG Fc-alka-
line phosphatase (AP) conjugated antibody (Jackson Im-dexamethasone treated and screened for fusion protein
production by Western blot analysis. Seven out of a total munoresearch, Westgrove, PA, USA), or with a rabbit
antipeptide polyclonal antibody made to the C-terminalof 24 clones exhibited strong, dexamethasone-inducible
sIg-PKD193 fusion protein expression. Two clones ex- 10 amino acid residues (PNNKVHPSST) of mouse poly-
cystin-1. Immunoreactive proteins were detected by usingpressing the strongest signals on initial screening, clones
18 and 20, were selected for further characterization. the AP chemiluminescent substrate CDP-Star (Tropix,
Bedford, MA, USA).One G418-resistant clone, clone 17, which did not show
expression of fusion protein, and one clone expressing
Immunofluorescencethe sIg-0 construct, clone 23, were also selected and used
in control experiments. For production of LacSwitch sta- Subconfluent cultures of M-1 and clone 20 cells grown
on glass coverslips were treated with 1mol/L dexameth-bly transfected cell lines, M-1 cells were transfected with
the Lac repressor expression vector, pCMVLacI, and asone for four hours and were either left unfixed or
fixed in methanol prior to incubation with fluoresceinwere grown under selection in medium containing 200
g/mL hygromycin. Approximately half of the hygro- isothiocyanate (FITC)-conjugated mouse anti-human
IgG monoclonal antibody (The Binding Site, Birming-mycin-resistant clonal lines were determined to constitu-
tively express high levels of the Lac repressor (LacI). ham, UK) at 4C. After washing, unfixed cells were then
postfixed in 4% paraformaldehyde/PBS, and both condi-One of the LacI-expressing lines was transfected with
the pOPRSVI/MCS-sIg-constructs and was grown under tions were visualized by fluorescence microscopy.
double selection. Hygromycin and G418-resistant clones
Bioelectric measurementswere screened for fusion protein production following
IPTG treatment. Clones expressing the highest levels of Monolayers of the parental M-1 cells and stably trans-
fected clones, grown on Snapwell membranes (Costar,the sIg-PKD193 (clone L2) and sIg-0 (clone L1) fusion
proteins with the lowest background expression were Cambridge, MA, USA), were mounted in modified Ussing
chambers as described previously [68, 74, 75]. The cham-chosen for further study.
bers contained 4 mL of medium (isotonic Ringer’s solu-
Northern blotting tion that contained no serum or serum components) and
were gassed and stirred with a slow stream of 5% CO2Total RNA was isolated from M-1 and clone 20 cells
by the method of Puissant and Houdebine [72]. Equal and 95% O2. The transepithelial potential difference, short-
circuit current, and monolayer resistance were determinedamounts of RNA (15 g) were denatured and electro-
phoresed in 2.2 mol/L formaldehyde–0.7% agarose gels. by techniques described previously [74, 75]. The mono-
layers were maintained in the short-circuited state, andGels were stained with acridine orange and photographed
to locate 18S and 28S rRNA bands and to verify the in- the open circuit voltage was determined at one- to five-
minute intervals. After a period of equilibration, mea-tegrity and equal loading of RNA samples. RNA was trans-
ferred to GeneScreen Plus membranes (DuPont-NEN, surements were made in sequential five-minute periods.
Steady-state short-circuit current was recorded after ad-Boston, MA, USA), baked, and hybridized. Prehybrid-
ization and hybridization conditions were as previously dition of agonists to the basolateral medium, typically
after 20 minutes.described [73]. Probes for hybridization were 32P-CTP-
labeled antisense RNAs generated from linearized 3 or
Cell proliferationinternal Pkd1 cDNA subclones by either SP6 or T7 RNA
polymerase. Following washing, Northern blots were ex- The Promega Cell Titer 96 MTT Assay method, as re-
ported by Rankin et al [76], was used to determine theposed to Kodak XAR film with Lightning Plus intensi-
fying screens for 2 days (short exposure) or 18 days (long relative rates of cell proliferation under different experi-
mental conditions. This method, which measures the opti-exposure).
cal density of a proliferation-dependent reaction product,
Western blotting was found to correlate directly with direct determinations
of cell number using the classic hemacytometer techniqueFor the analysis of fusion protein production, cells
were lysed in boiling 2  Laemmli loading buffer [125 [68]. The relationship between cell number and optical
density was linear. To determine the effects of agonistsmmol/L Tris-HCl, pH 6.8, 20% glycerol, 4% sodium do-
decyl sulfate (SDS), 2% 2-mercaptoethanol], and the total on the rate of proliferation, the same numbers of cells
(2000) were seeded into individual chambers of a 96-cell lysates were electrophoresed in 10% polyacrylamide-
sodium dodecyl sulfate gels. Proteins were transferred well plate. The cells were incubated initially in DMEM/
F12 medium supplemented only with penicillin, strepto-to Immobilon P membranes (Millipore, Bedford, MA,
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mycin, ITS (insulin, transferrin, selenium), and 1% FBS.
After one day, the FBS was reduced to 0.002% (ITS
deleted), and the cells were treated with dexamethasone.
Specific agonists or inhibitors were added after two days
of culture. Inhibitors H-89, Rp-cAMP, genistein, and
PD98059 were added for 30 minutes before the agonists.
The agonists were used at the following concentrations:
8-Br-cAMP (100mol/L), forskolin (10mol/L), arginine
vasopressin (AVP; 100 mU/mL), desmopressin (DDAVP;
100 mU/mL), secretin (1 mol/L), vasoactive intestinal
polypeptide (VIP; 1mol/L), and prostaglandin E2 (PGE2;
25 ng/mL). The inhibitors were used at the following con-
centrations: H-89 (10 mol/L), Rp-cAMP (250 mol/L),
genistein (40 mol/L), PD98059 (50 mol/L).
Reagents
Fig. 1. Fusion protein constructs and protein expression. (A) The poly-
8-Br-cAMP, forskolin, AVP, secretin, VIP, PGE2, and cystin-1 C-terminal domain construct sIg-PKD193 encodes the C-termi-
nal 193 amino acids of mouse polycystin-1 (PKD193) fused to the CD7genistein were obtained from Sigma (St. Louis, MO,
transmembrane domain (TM), the CH2-CH3 domains of human IgG,USA). PD98059 was obtained from New England Bio- and the CD5 signal sequence (SS). The control construct sIg-0 contains
labs (Beverly, MA, USA). DDAVP was obtained from the CD7 transmembrane domain, the CH2-CH3 domains, and the CD5
signal sequence, but lacks the polycystin-1 C-terminal tail. These con-Rhone-Poulenc Rorer Pharmaceuticals (Collegeville,
structs were cloned into the dexamethasone-inducible eukaryotic ex-PA, USA). pression vector pLK-neo [70]. (B) Western blots showing the presence
or absence of the Ig-PKD193 and Ig-0 fusion proteins in whole cell
Statistics lysates from the parental M-1 cells and clones 17, 18, 20, and 23, follow-
ing treatment () or no treatment () with 1 mol/L dexamethasoneMean and SEM were calculated, and levels of signifi- (Dex) for 24 hours, using antibodies to the N-terminus (anti-IgG) and
cance (P  0.05) were determined by the unpaired t test. the C-terminus (anti-PKD). Clones 17, 18, and 20 were stably trans-
fected with the dexamethasone-inducible sIg-PKD193 construct (clone
17 was G418 resistant, but did not express detectable levels of the Ig-
PKD193 fusion protein). Clone 23 was stably transfected with the con-RESULTS
trol sIg-0 construct.
The mouse M-1 cell line, which was derived from the
kidneys of an SV40 transgenic mouse, has a highly differ-
entiated cell culture morphology with a polarized epithe-
human IgG antibody and a polyclonal anti-polycystin-1lial phenotype [71]. Its cortical collecting duct origin was
peptide antibody. While clone 17 was G418 resistant, itconsidered an advantage for examining the function of
had no detectable fusion protein expression; clones 18polycystin-1, since the collecting duct expresses polycys-
and 20 had significant dexamethasone-induced expres-tin-1 in the developing and mature adult kidney [28].
sion. Figure 1 also shows the expression of a controlM-1 cell lines stably expressing a membrane-targeted
fusion protein that was encoded by a DNA constructpolycystin-1 C-terminal domain were made using a DNA
containing only the signal sequence, the human IgG do-construct encoding the C-terminal 193 amino acids of
mains, and the transmembrane segment (Ig-0). This con-mouse polycystin-1 (sIg-PKD193; Fig. 1A). This region
struct was used to generate clone 23, which showed aof polycystin-1 has been shown to bind and activate het-
low level of constitutive expression, but lacked dexa-erotrimeric G proteins, to bind RGS7 and polycystin-2,
methasone-inducibility. Figure 2 shows that the parentaland to initiate signal transduction leading to the activa-
M-1 cells express the 14 kb native polycystin-1 mRNAtion of PKC, JNK, and AP-1 and to the stabilization of
(PKD1), and that clone 20 expresses both the native-catenin [60–63, 66, 67]. The sIg-PKD193 construct was
PKD1 mRNA and the dexamethasone-inducible PKD193cloned into the pLK-neo expression vector, which was
mRNA.developed for high level kidney-specific expression
When cells were grown at low density, the Ig-PKD193driven by a dexamethasone-inducible MMTV LTR iso-
fusion protein showed cell surface, plasma membranelated from a kidney adenocarcinoma cell line [70]. Three
expression, as determined by immunofluorescence mi-G418-resistant cell lines, clones 17, 18, and 20, with differ-
croscopy using an anti-human IgG antibody, which isent levels of dexamethasone-inducible fusion protein ex-
specific for the extracellular, human IgG domain of thepression were examined.
fusion protein (Fig. 3). When cells were grown to conflu-Figure 1B shows the expression of the Ig-PKD193
ence on permeable supports, the parental M-1 cells andfusion protein in clones 17, 18, and 20. Protein expression
was examined using two different antibodies, an anti- clones 17, 18, and 20 displayed electrical resistances in
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(hence, negative values in Fig. 4). In contrast, the cultures
expressing the polycystin-1 fusion protein (clones 18 and
20) showed larger increases in cell number when treated
with cAMP as compared with control medium lacking
cAMP (hence, positive values in Fig. 4). To confirm that
the increased cell proliferation seen in clones 18 and 20
was not due to a nonspecific effect of dexamethasone,
stably transfected cell lines expressing the Ig-0 (clone
L1) and Ig-PKD193 (clone L2) fusion proteins were also
constructed using the IPTG-inducible LacSwitch (Stra-
tagene) mammalian expression system. As can be seenFig. 2. Polycystin-1 mRNA expression in M-1 and clone 20 cells. (A)
Northern blot showing total RNA from M-1 and clone 20 cells, following in Figure 4B, IPTG induction of the Ig-PKD193 fusion
treatment () or no treatment () with 0.01 mol/L dexamethasone protein (L2), but not the Ig-0 fusion protein (L1), re-(Dex) for 12 hours, and hybridized with a 32P-labeled probe specific to
sulted in an increased rate of cell proliferation in re-the 3 end of the polycystin-1 coding region. The long autoradiographic
exposure shows the 14 kb native PKD1 mRNA (PKD1) in both the sponse to cAMP treatment.
M-1 cells and clone 20. The short autoradiographic exposure shows the To assess cell proliferation over an extended timeabundant 2.3 kb sIg-PKD193 transcript (PKD193). The smear of
course, growth curves were generated for clones 17 andradioactivity between the 14 and 2.3 kb bands probably represents
constitutively expressed transcripts from multiple, randomly integrated 20 over a six-day period in the presence of 1 mol/L
sIg-PKD193 constructs that do not give rise to intact fusion protein. dexamethasone, with and without cAMP treatment. CellThe position of 28S ribosomal RNA is shown. (B) Northern blot showing
numbers were determined by direct cell counting. Astotal RNA from M-1 and clone 20 cells, following treatment () or
no treatment () with 0.01 mol/L dexamethasone for 12 hours, and shown in Figure 5, 8-Br-cAMP had opposite effects on
hybridized with a 32P-labeled probe specific to the transmembrane region the two clones, stimulating cell growth in clone 20 butof polycystin-1 (internal probe) to confirm the presence of the 14 kb
inhibiting cell growth in clone 17, thus confirming thePKD1 RNA, and a lack of hybridization to the sIg-PKD193 RNA.
results in Figure 4. The Western blot in Figure 5 shows
fusion protein levels at one, two, three, and four days
of culture, indicating that protein levels were induced in
excess of 100 ohm/cm2 in both the presence and absence clone 20 early in the time course and persisted through
of dexamethasone (data not shown), indicating that they at least four days of culture in the continued presence
are capable of forming epithelial monolayers. In addi- of dexamethasone.
tion, the parental M-1 cells and clones 17, 18, and 20 Dexamethasone induction of fusion protein expres-
grown in both the presence and absence of dexametha- sion had a significant effect on stimulating cell growth
sone had similar forskolin-induced chloride currents in the presence of cAMP in clones 18 and 20 (Fig. 4).
(data not shown). Thus, the expression of the polycystin-1 To determine whether there was a correlation between
fusion protein did not seem to significantly affect the fusion protein levels and stimulation of cell proliferation,
electrophysiological response of these cells to increased clone 20 was treated with cAMP in the presence of vari-
levels of intracellular cAMP. ous concentrations of dexamethasone from 0.1 nmol/L
To determine whether polycystin-1 fusion protein ex- to 1 mol/L, and cell numbers were determined at three
pression affected the proliferation of the cells in response days of culture. Figure 6 shows that increasing levels
to cAMP, the growth of the parental M-1 cells and clones of dexamethasone in the presence of cAMP resulted in
17, 18, 20, and 23 was compared in the presence and increasing cell numbers (Fig. 6A) and that the fusion pro-
absence of dexamethasone, with and without cAMP tein was induced equally well in the presence or absence
treatment (Fig. 4A). Cells were seeded at low density in of cAMP over a range of dexamethasone concentrations
microtiter plates and were treated at 24 hours with 1 (Fig. 6B). This suggests that the cAMP-responsive cell
mol/L dexamethasone to induce fusion protein expres- proliferation of these cells is a function of the amount
sion in the clones. At 48 hours, half of the cultures were of polycystin-1 fusion protein expressed in the cells.
treated with 8-Br-cAMP using a dose known to elicit a To determine whether treatments to elevate endoge-
maximal growth response in these cells. In this experi- nous levels of cAMP would have the same effect as
ment, relative rates of cell proliferation were assessed treatment by exogenous 8-Br-cAMP, the parental M-1
at the end of 96 hours by determining changes in cell cells and clones 17, 20, and 23 were treated with a number
number with the Promega MTT assay. While cell num- of cAMP agonists in the presence of 1 mol/L dexameth-
bers increased in all cases when the cultures were treated asone, and cell growth was assayed at four days of cul-
with cAMP, the cultures not expressing the polycystin-1 ture. As shown in Figure 7, growth of the parental M-1
fusion protein (M-1 cells and clones 17 and 23) showed cells and clones 17 and 23 was inhibited by every one of
smaller increases in cell number when treated with the agonists, whereas growth of clone 20 was stimulated.
These observations suggest that the inhibition of cellcAMP as compared with control medium lacking cAMP
Sutters et al: cAMP, polycystin-1, and cell growth 489
Fig. 3. Cell surface expression of the Ig-
PKD193 fusion protein. Immunofluorescence
analysis was carried out using a fluorescein-
conjugated anti-IgG Fc antibody and per-
meablized (A and C) or nonpermeabilized (B
and D) M-1 cells (A and B) or clone 20 cells
(C and D). Cells were treated with 1 mol/L
dexamethasone for four hours to induce fu-
sion protein expression. Cells that were per-
meabilized by methanol fixation show internal
labeling for Ig-PKD193 fusion protein (C) in
patterns that correspond to the intracellular
biosynthetic pathway. In contrast, when anti-
IgG Fc was incubated at 4C with unfixed
(nonpermeabilized) cells, antibody bound spe-
cifically to the outer, plasma membrane of cell
surfaces (D). Inserts in (C) and (D) show
higher power views of permeabilized and non-
permeabilized cells, respectively. Control M-1
cells were negative under both conditions (A
and B).
Fig. 4. Cell proliferation in response to cAMP treatment. The growth
of M-1 cells and clones 17, 18, 20, 23, L1, and L2 was compared, with
and without cAMP treatment, in the absence ( ) or presence ()
of either dexamethasone (A) or IPTG (B) to induce fusion protein
expression. Bars reflect either an increased growth rate (positive values)
or a decreased growth rate (negative values) following treatment with Fig. 5. Time course of cell proliferation in response to cAMP treat-
cAMP. Cells were seeded at low density in microtiter plates and after ment. (A) Growth curves for clone 17 () and clone 20 () were
one day in culture were treated with either 1 mol/L dexamethasone generated over a six-day period in the presence of 1 mol/L dexametha-
(Dex) or 1 mmol/L IPTG. At two days, half the cultures were treated sone (added after culturing 1 day). At 2 days, cultures were treated
with 8-Br-cAMP. Relative rates of cell proliferation in the treated and with 8-Br-cAMP (solid lines) or were not treated (dashed lines). Cell
untreated cultures were determined at the end of four days of culture number was determined by direct cell counting. Each time point repre-
for the dexamethasone treatment (the last 3 days in the presence of sents the average of at least three separate cultures; error bars are
Dex) or at the end of five days of culture for the IPTG treatment (the standard errors of the mean. Note that clone 20 proliferated more
last 4 days in the presence of IPTG) by measuring changes in cell rapidly than clone 17 in the absence of cAMP. cAMP treatment had
number with the Promega MTT assay and are expressed as a percent opposite effects on the two clones, stimulating cell proliferation in clone
change in cell proliferation resulting from the cAMP treatment. Each 20 but inhibiting cell proliferation in clone 17. All points at day 4 and
bar represents the average of at least three separate cultures; error bars after were significantly different from each other (P  0.05). (B) West-
are standard errors of the mean. Significant differences (P  0.05) ern blot using the anti-IgG antibody showing Ig-PKD193 fusion protein
between the cAMP treated and untreated cultures are indicated by levels at 1-4 days of culture in the absence () and presence () of 1
asterisks. mol/L Dex.
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Fig. 7. Cell proliferation in response to cAMP agonists. M-1 cells ( )
and clones 17 ( ), 20 (), and 23 ( ) were treated in the presence
of 1mol/L dexamethasone with 8-Br-cAMP or with the cAMP agonists
forskolin, AVP, DDAVP, secretin, VIP, or PGE2. Cells were seeded
at low density and after 1 day in culture were treated with dexametha-
sone. At 2 days, half the cultures were treated with 8-Br-cAMP or with
Fig. 6. cAMP-responsive cell proliferation as a function of the level the cAMP agonists. Relative rates of cell proliferation in the treated
of dexamethasone. (A) Clone 20 cells were grown in the presence of and untreated cultures were determined at the end of 4 days of culture
8-Br-cAMP following treatment with various concentrations of dexa- (the last 3 days in the presence of dexamethasone) using the Promega
methasone (Dex) from 0.1 nmol/L to 1 mol/L. Cells were seeded at MTT assay. Bars reflect either an increased growth rate (positive values)
low density and after 1 day in culture were either treated or not treated or a decreased growth rate (negative values) following treatment with
with dexamethasone. At 2 days, all of the cultures were grown in the cAMP. Each bar represents the average of at least three separate
presence of 8-Br-cAMP. Relative rates of cell proliferation in the treated cultures; error bars are standard errors of the mean. All of the treatments
and untreated cultures were determined at the end of 4 days of culture resulted in significant differences (P  0.05) in cell growth. Growth of
(the last 3 days in the presence of dexamethasone) using the Promega the M-1 cells and clones 17 and 23 was inhibited by every one of
MTT assay. Each bar represents the average of at least three separate the agonists, whereas growth of clone 20 was stimulated. The similar
cultures; error bars are standard errors of the mean. Significant differ- responses of all the cell lines to the agonists indicate that all the clones
ences (P  0.05) between the dexamethasone-treated and -untreated (clones 17, 20, and 23) have intact, receptor-mediated signaling systems.
cultures are indicated by asterisks. This experiment shows that the
cAMP-responsive cell proliferation of clone 20 is a function of the
amount of polycystin-1 fusion protein expressed in the cells. (B) Western
blot using anti-IgG antibody showing that the Ig-PKD193 fusion protein
was induced equally well in the presence or absence of cAMP over the
range of dexamethasone concentrations from 1 nmol/L to 1 mol/L. 20 in the presence or absence of cAMP, indicating that
receptor tyrosine kinase pathways were not responsible
for the proliferation of these cells (Fig. 8). In contrast, the
MEK inhibitor PD98059 reversed the cAMP-induced
proliferation in the parental M-1 cells and in clones 17 increase in cell proliferation of clone 20, causing an inhi-
and 23 and the stimulation of cell proliferation in clone 20 bition of cell proliferation (Fig. 8). This result suggests
were due to a modulation of receptor-mediated, cAMP- that the cAMP stimulation of cell growth of clone 20
driven mechanisms, and thus that all of the clones have must involve signaling through the mitogen-activated
intact signaling pathways. protein kinase (MAPK) pathway.
To determine the extent to which cell proliferation
was affected by endogenous levels of cAMP, the parental
DISCUSSIONM-1 cells and clones 17 and 20 were treated with the
competitive inhibitor of cAMP, Rp-cAMP, or the PKA This article shows that a polycystin-1 C-terminal do-
inhibitor H-89. Figure 8 shows the results for cell growth main construct stably expressed as a membrane-targeted
assays in the presence of 8-Br-cAMP, Rp-cAMP, and fusion protein is capable of inducing a change in the growth
H-89. Treatment of the M-1 cells with the inhibitors properties of M-1 cells in response to cAMP. The growth
resulted in a stimulation of cell growth, and treatment of wild-type M-1 cells was inhibited by 8-Br-cAMP and
of clone 20 cells with the inhibitors resulted in an inhibi- by cAMP agonists, whereas the growth of clones 18 and
tion of cell growth, suggesting that there was endogenous 20, which express the polycystin-1 fusion protein, was
cAMP in both of these cells. Clone 17 was largely unaf- stimulated. Expression of the polycystin-1 construct was
fected by the cAMP inhibitors, suggesting that it had under the control of the dexamethasone-responsive
low endogenous levels of cAMP. MMTV promoter, thus making it possible to show that
The tyrosine kinase inhibitor genistein did not affect the degree of growth stimulation correlated with the
amount of dexamethasone-inducible fusion protein ex-the growth of the parental M-1 cells and clones 17 and
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phenotype of these cells from one that was inhibited by
cAMP to one that was stimulated by cAMP, rather than
simply altering the degree of cAMP-responsiveness of
these cells. This effect of the fusion protein was not
related to a change in the levels of cAMP, since all cell
lines responded by increasing their cAMP levels when
treated with the cAMP agonists. Thus, it is not the level
of cAMP but the growth response to the cAMP that
distinguishes these two phenotypes.
The proliferation of the parental M-1 cells and the
stably transfected clones did not appear to depend on
receptor or nonreceptor tyrosine kinases, since genistein
had little or no effect on the growth of any of these cells
Fig. 8. Inhibition of cAMP-induced cell proliferation. M-1 cells ( ) in either the presence or absence of cAMP. In contrast,and clones 17 ( ), and 20 () were treated in the presence of 1 mol/L
the growth of both the parental M-1 cells and the stablydexamethasone with 8-Br-cAMP; with the cAMP antagonist, Rp-
cAMP; with the PKA inhibitor, H-89; with the tyrosine kinase inhibitor, transfected clones was affected by the PKA inhibitors
genistein; with a combination of 8-Br-cAMP and genistein, or with a Rp-cAMP and H-89. We conclude that cAMP acts throughcombination of 8-Br-cAMP and the MEK1 inhibitor, PD98059. Cells
PKA to regulate cell proliferation in these cell lines, butwere seeded at low density and after 1 day in culture were placed in
medium with dexamethasone. At 2 days, half the cultures were treated in opposite ways. Thus, in the wild-type cells, cAMP acts
with the various agonists or inhibitors. Relative rates of cell proliferation to inhibit cell proliferation, whereas in the polycystin-in the treated and untreated cultures were determined at the end of 4
transformed cells, cAMP acts to stimulate cell prolifera-days of culture (the last 3 days in the presence of dexamethasone) using
the Promega MTT assay. Bars reflect either an increased growth rate tion (Fig. 9). Our experiments have not identified the
(positive values) or a decreased growth rate (negative values) following cellular pathway that is blocked by cAMP in the wild-treatment. Each bar represents the average of at least three separate
type cells. However, use of the MEK1 inhibitor PD98059cultures; error bars are standard errors of the mean. Significant differ-
ences (P  0.05) between the (agonist and/or inhibitor) treated and showed that cAMP acts to stimulate a MEK-dependent
untreated cultures are indicated by asterisks. pathway in the polycystin-transformed cells (Fig. 9).
The mechanism by which overexpression of the poly-
cystin-1 construct transforms the M-1 phenotype is pres-
ently not known. The polycystin-1 C-terminal tail stablypression. It is unlikely that the growth stimulation in
response to cAMP was due simply to the pLK-neo con- binds a number of proteins, including heterotrimeric G
proteins [63]; the regulator of G-protein signaling, RGS7struct or to a nonspecific effect of the dexamethasone
since two of the stably transfected clones had wild-type [61]; and polycystin-2 [66, 67]. The C-terminal tail also
appears to be a substrate for PKA and a Src-like tyrosinecAMP responsiveness: clone 17, which was transfected
with the polycystin-1 construct but did not express de- kinase [64, 65]. In addition, transient transfection of
membrane-targeted human C-terminal constructs, verytectable fusion protein, and clone 23, which was stably
transfected with a fusion protein lacking the polycystin-1 similar to the mouse construct used in these studies, led
to activation of AP-1 in a JNK and rac1/cdc42-dependentC-terminal tail. Furthermore, a stably transfected clone
that was constructed with the Stratagene LacSwitch ex- and PKC-dependent manner [60] and to inhibition of
GSK-3 and stabilization of -catenin [62]. Thus, thepression system, in which IPTG was used to induce poly-
cystin-1 C-terminal domain fusion protein expression, polycystin-1 C-terminal tail is capable of exerting effects
on a number of signaling pathways, any one of whichalso showed growth stimulation in response to cAMP.
The stably transfected clones appeared to be morpho- could be responsible for phenotypic conversion. One
interpretation of the results is that overexpression of thelogically unaltered by overexpression of the fusion pro-
tein. Like the parental M-1 cells, the clones formed epi- C-terminal cytosolic tail acts in a dominant interfering
manner by binding and sequestering polycystin-1 bindingthelial monolayers on permeable supports and displayed
forskolin-stimulated net transepithelial anion currents proteins or by overactivating a polycystin-mediated sig-
naling pathway that then feeds back and inhibits native(data not shown). In addition, all of the cell lines showed
growth stimulation in response to EGF regardless of polycystin function. This mechanism would be consistent
with the observation that transgenic overexpression ofwhether the fusion protein was expressed (data not
shown). All of the clones showed increases in cAMP a full-length PKD1 construct gives rise to polycystic kid-
neys [41]. The observation that M-1 cells express polycys-levels (data not shown) in response to forskolin, AVP,
DDAVP, secretin, VIP, and PGE2, indicating that they tin-1 mRNA suggests that a dominant-negative effect is
feasible.all contain normally functioning receptor-mediated sig-
naling pathways. Analysis of human PKD1 mutations has shown that
most of them cause protein truncation and thus are likelyExpression of the polycystin-1 construct converted the
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Fig. 9. Responses of wild-type and polycys-
tin-transformed cells to cAMP treatment. (A)
Basal growth (no cAMP treatment) character-
istics of control cell lines (wild-type, parental
M-1 cells, and clones 17 and 23) and cells
transformed by expression of the truncated
polycystin-1 construct (clones 18 and 20). Both
types of cells have some endogenous cAMP,
which causes an inhibition of cell proliferation
in the wild-type cells and a stimulation of cell
proliferation in the polycystin-transformed
cells. These effects were demonstrated by the
inhibitors, Rp-cAMP and H-89. These inhibi-
tors had opposite effects on the growth of the
wild-type and polycystin-transformed cells, al-
leviating the growth inhibition by endogenous
cAMP in the wild-type cells and thereby stim-
ulating their proliferation, and blocking the
growth stimulation by cAMP in the polycystin-
transformed cells and thereby inhibiting their
proliferation (see Fig. 8). Under basal growth
conditions (in the absence of exogenous cAMP),
the polycystin-transformed cells have an intrin-
sically higher rate of cell proliferation than
the non-expressing control cell lines, due most
likely to this endogenous cAMP (see Fig. 5).
(B) Growth following cAMP treatment. Treat-
ment of wild-type cells or polycystin-trans-
formed cells with 8-Br-cAMP or with cAMP
agonists further inhibited the proliferation of
the wild-type cells and further stimulated the
proliferation of the polycystin-transformed
cells (see Fig. 7). The 8-Br-cAMP stimulation
of the polycystin-transformed cells was inhib-
ited by PD98059, indicating that the cAMP-
stimulated pathway requires MEK (see Fig. 8).
to cause loss of polycystin-1 function [32–36, 46]. It also like human ADPKD cells provides evidence that a loss
is possible, however, that PKD is caused by a gain-of- or gain of polycystin-1 function is directly responsible
function mechanism. If overexpression of the C-terminal for the abnormal cAMP-responsive cell growth pheno-
polycystin-1 construct gives rise to a loss or gain of poly- type in human ADPKD.
cystin-1 function, the M-1 cells expressing the C-terminal
construct should have a similar phenotype to human ACKNOWLEDGMENTS
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